Neuroprotective effects of a specific multi-nutrient intervention against Aβ42-induced toxicity in rats

[1]  P. Kamphuis,et al.  Docosahexaenoic acid reduces amyloid-β(1-42) secretion in human AβPP-transfected CHO-cells by mechanisms other than inflammation related to PGE₂. , 2010, Journal of Alzheimer's disease : JAD.

[2]  G. Eckert,et al.  Lipid Membranes and β-Amyloid: A Harmful Connection , 2010 .

[3]  J. Parodi,et al.  Synaptotoxicity of Alzheimer Beta Amyloid Can Be Explained by Its Membrane Perforating Property , 2010, PloS one.

[4]  C. V. von Arnim,et al.  More than the sum of its parts? Nutrition in Alzheimer's disease. , 2010, Nutrition.

[5]  Yaakov Stern,et al.  Food combination and Alzheimer disease risk: a protective diet. , 2010, Archives of neurology.

[6]  P. Scheltens,et al.  Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial , 2010, Alzheimer's & Dementia.

[7]  O. Shido,et al.  Mechanism of docosahexaenoic acid‐induced inhibition of in vitro Aβ1–42 fibrillation and Aβ1–42‐induced toxicity in SH‐S5Y5 cells , 2009, Journal of neurochemistry.

[8]  R. Wurtman,et al.  Use of phosphatide precursors to promote synaptogenesis. , 2009, Annual review of nutrition.

[9]  B. Kriem,et al.  The essential role of lipids in Alzheimer's disease. , 2009, Biochimie.

[10]  D. Kögel,et al.  The interaction of beta-amyloid protein with cellular membranes stimulates its own production. , 2009, Biochimica et biophysica acta.

[11]  D. Steel,et al.  Amyloid-beta membrane binding and permeabilization are distinct processes influenced separately by membrane charge and fluidity. , 2009, Journal of molecular biology.

[12]  H. Arai,et al.  Docosahexaenoic acid disrupts in vitro amyloid β1‐40 fibrillation and concomitantly inhibits amyloid levels in cerebral cortex of Alzheimer’s disease model rats , 2008, Journal of neurochemistry.

[13]  P. Kamphuis,et al.  The potential role of nutritional components in the management of Alzheimer's Disease. , 2008, European journal of pharmacology.

[14]  A. Esteras-Chopo,et al.  Amyloid toxicity is independent of polypeptide sequence, length and chirality. , 2008, Journal of molecular biology.

[15]  N. Arispe,et al.  The Cell-Selective Neurotoxicity of the Alzheimer's Aβ Peptide Is Determined by Surface Phosphatidylserine and Cytosolic ATP Levels. Membrane Binding Is Required for Aβ Toxicity , 2007, The Journal of Neuroscience.

[16]  R. Wurtman,et al.  Chronic administration of docosahexaenoic acid or eicosapentaenoic acid, but not arachidonic acid, alone or in combination with uridine, increases brain phosphatide and synaptic protein levels in gerbils , 2007, Neuroscience.

[17]  J. Kornhuber,et al.  Non-pharmacologic prevention of Alzheimer’s disease: nutritional and life-style risk factors , 2007, Journal of Neural Transmission.

[18]  J. Strosznajder,et al.  Inhibitor of cyclooxygenase-2 protects against amyloid beta peptide-evoked memory impairment in mice. , 2007, Pharmacological reports : PR.

[19]  B. Penke,et al.  Synthesis of Aβ[1‐42] and its derivatives with improved efficiency , 2007, Journal of peptide science : an official publication of the European Peptide Society.

[20]  T. Nabeshima,et al.  Effects of a Novel Cognitive Enhancer, Spiro[imidazo-[1,2-a]pyridine-3,2-indan]-2(3H)-one (ZSET1446), on Learning Impairments Induced by Amyloid-β1–40 in the Rat , 2006, Journal of Pharmacology and Experimental Therapeutics.

[21]  Yaakov Stern,et al.  Mediterranean diet and risk for Alzheimer's disease , 2006, Annals of neurology.

[22]  George E. Marzloff,et al.  Synaptic proteins and phospholipids are increased in gerbil brain by administering uridine plus docosahexaenoic acid orally , 2006, Brain Research.

[23]  P. Tariot.  Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies. , 2006, The Journal of clinical psychiatry.

[24]  Michio Hashimoto,et al.  Docosahexaenoic acid-induced amelioration on impairment of memory learning in amyloid beta-infused rats relates to the decreases of amyloid beta and cholesterol levels in detergent-insoluble membrane fractions. , 2005, Biochimica et biophysica acta.

[25]  Jian-jun Wang,et al.  RETRACTED: Neurochemical and behavioral effects of the intrahippocampal co-injection of β-amyloid protein1-40 and Ibotenic acid in rats , 2005 .

[26]  D. Westaway,et al.  Interactions between beta-amyloid and central cholinergic neurons: implications for Alzheimer's disease. , 2004, Journal of psychiatry & neuroscience : JPN.

[27]  Takashi Morihara,et al.  Docosahexaenoic Acid Protects from Dendritic Pathology in an Alzheimer's Disease Mouse Model , 2004, Neuron.

[28]  Kazuro Furukawa,et al.  Overexpressed GM1 Suppresses Nerve Growth Factor (NGF) Signals by Modulating the Intracellular Localization of NGF Receptors and Membrane Fluidity in PC12 Cells* , 2004, Journal of Biological Chemistry.

[29]  Nathan Herrmann,et al.  Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[30]  Pahud Gabrielle,et al.  Cytosolic Choline Acetyltransferase Binds Specifically to Cholinergic Plasma Membrane of Rat Brain Synaptosomes to Generate Membrane-Bound Enzyme , 2003, Neurochemical Research.

[31]  M. Giovannini,et al.  β-Amyloid-Induced Inflammation and Cholinergic Hypofunction in the Rat Brain in Vivo: Involvement of the p38MAPK Pathway , 2002, Neurobiology of Disease.

[32]  S. Kawashima,et al.  Antiamnesic effects of azaindolizinone derivative ZSET845 on impaired learning and decreased ChAT activity induced by amyloid-β 25–35 in the rat , 2002, Brain Research.

[33]  P. Lansbury,et al.  Neurodegenerative disease: Amyloid pores from pathogenic mutations , 2002, Nature.

[34]  R. Lal,et al.  Amyloid β protein forms ion channels: implications for Alzheimer's disease pathophysiology , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[35]  J. Pettegrew,et al.  Brain Membrane Phospholipid Alterations in Alzheimer's Disease , 2001, Neurochemical Research.

[36]  S. Kawashima,et al.  Effects of amyloid-beta-(25-35) on passive avoidance, radial-arm maze learning and choline acetyltransferase activity in the rat. , 2001, European journal of pharmacology.

[37]  T. Bayer,et al.  Key Factors in Alzheimer's Disease: β‐amyloid Precursor Protein Processing, Metabolism and Intraneuronal Transport , 2001, Brain pathology.

[38]  K. Shiba,et al.  Reduction of vesicular acetylcholine transporter in β-amyloid protein-infused rats with memory impairment , 2000, Nuclear medicine communications.

[39]  S. Younkin,et al.  Biochemical detection of Aβ isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer’s disease , 2000 .

[40]  A. King,et al.  The question of familial meningiomas and schwannomas: , 2000, Neurology.

[41]  C. Berr.  [Epidemiology of Alzheimer's disease]. , 1999, Servir.

[42]  L. Giovannelli,et al.  Long-term changes in the aggregation state and toxic effects of β-amyloid injected into the rat brain , 1998, Neuroscience.

[43]  S. Love,et al.  Frontal cortical synaptophysin in Lewy body diseases: relation to Alzheimer’s disease and dementia , 1998, Journal of neurology, neurosurgery, and psychiatry.

[44]  T. Harkany,et al.  induces behavioral dysfunctions, impairs learning and memory and disrupts cortical cholinergic innervation , 1998 .

[45]  M. Mattson.  Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. , 1997, Physiological reviews.

[46]  J. McLaurin,et al.  Membrane Disruption by Alzheimer β-Amyloid Peptides Mediated through Specific Binding to Either Phospholipids or Gangliosides , 1996, The Journal of Biological Chemistry.

[47]  C. Gottfries,et al.  Membrane Components Separate Early-Onset Alzheimer's Disease From Senile Dementia of the Alzheimer Type , 1996, International Psychogeriatrics.

[48]  C. Barnes,et al.  Neuropathology of synthetic β-amyloid peptide analogs in vivo , 1996, Brain Research.

[49]  H. Yi,et al.  Expression of the putative vesicular acetylcholine transporter in rat brain and localization in cholinergic synaptic vesicles , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[50]  T. Harkany,et al.  β-Amyloid(1–42) affects cholinergic but not parvalbumin-containing neurons in the septal complex of the rat , 1995, Brain Research.

[51]  S. Yamamoto,et al.  Administration of phosphatidylcholine increases brain acetylcholine concentration and improves memory in mice with dementia. , 1995, The Journal of nutrition.

[52]  L. Giovannelli,et al.  Differential effects of amyloid peptides β-(1–40) and β-(25–35) injections into the rat nucleus basalis , 1995, Neuroscience.

[53]  H. Okuyama,et al.  Effect of a high alpha-linolenate and high linoleate diet on membrane-associated enzyme activities in rat brain--modulation of Na+, K+- ATPase activity at suboptimal concentrations of ATP. , 1995, Biological & pharmaceutical bulletin.

[54]  F. Amenta,et al.  Effect of ipsilateral lesioning of the nucleus basalis magnocellularis and of l-α-glyceryl phosphorylcholine treatment on choline acetyltransferase and acetylcholinesterase in the rat fronto-parietal cortex , 1993, Neuroscience Letters.

[55]  F. Amenta,et al.  Cholinergic Neurotransmission in the Hippocampus of Aged Rats: Influence of L‐α‐Glycerylphosphorylcholine Treatment , 1993, Annals of the New York Academy of Sciences.

[56]  P. Govitrapong,et al.  Partial restoration of choline acetyltransferase activities in aging and AF64A-lesioned rat brains by vitamin E , 1993, Neurochemistry International.

[57]  J. Growdon,et al.  Evidence for a membrane defect in Alzheimer disease brain. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[58]  S. Kish,et al.  Learning is improved by a soybean oil diet in rats. , 1986, Life sciences.

[59]  E. Bennett,et al.  Effects of dietary choline on memory and brain chemistry in aged mice , 1985, Neurobiology of Aging.

[60]  H. Henke,et al.  Cholinergic enzymes in neocortex, hippocampus and basal forebrain of non-neurological and senile dementia of alzheimer-type patients , 1983, Brain Research.

[61]  P. Mcgeer,et al.  Choline acetyltransferase immunohistochemistry in brains of alzheimer's disease patients and controls , 1983, Neuroscience Letters.

[62]  E. P. Kennedy,et al.  The function of cytidine coenzymes in the biosynthesis of phospholipides. , 1956, The Journal of biological chemistry.

[63]  Mood and Anxiety Related Phenotypes in Mice , 2011, Neuromethods.

[64]  K. Yaffe,et al.  Targets for the prevention of dementia. , 2010, Journal of Alzheimer's disease : JAD.

[65]  C. Masters,et al.  Histidine 14 modulates membrane binding and neurotoxicity of the Alzheimer's disease amyloid-beta peptide. , 2010, Journal of Alzheimer's disease : JAD.

[66]  P. Scheltens,et al.  Can nutrients prevent or delay onset of Alzheimer's disease? , 2010, Journal of Alzheimer's disease : JAD.

[67]  G. Eckert,et al.  Lipid membranes and beta-amyloid: a harmful connection. , 2010, Current protein & peptide science.

[68]  Todd D. Gould,et al.  The open field test. , 2009 .

[69]  K. Buckwalter,et al.  Evidence supporting nutritional interventions for persons in early stage Alzheimer’s disease (AD) , 2008, The journal of nutrition, health & aging.

[70]  S. Scheff,et al.  Alzheimer's disease-related alterations in synaptic density: neocortex and hippocampus. , 2006, Journal of Alzheimer's disease : JAD.

[71]  Jian-jun Wang,et al.  Neurochemical and behavioral effects of the intrahippocampal co-injection of beta-amyloid protein1-40 and ibotenic acid in rats. , 2005, Life Science.

[72]  J. Kaye,et al.  Differential loss of synaptic proteins in Alzheimer's disease: implications for synaptic dysfunction. , 2005, Journal of Alzheimer's disease : JAD.

[73]  G. Eckert,et al.  Membrane disordering effects of beta-amyloid peptides. , 2005, Sub-cellular biochemistry.

[74]  W. Markesbery,et al.  Regional Membrane Phospholipid Alterations in Alzheimer's Disease , 2004, Neurochemical Research.

[75]  Di Sha,et al.  Choline Acetyltransferase: Regulation and Coupling with Protein Kinase and Vesicular Acetylcholine Transporter on Synaptic Vesicles , 2004, Neurochemical Research.

[76]  S. Younkin,et al.  Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. , 2000, Biochimica et biophysica acta.

[77]  A. Hofman,et al.  Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. , 2000, Neurology.

[78]  C. Barnes,et al.  Neuropathology of synthetic beta-amyloid peptide analogs in vivo. , 1996, Brain Research.

[79]  L. Giovannelli,et al.  Differential effects of amyloid peptides beta-(1-40) and beta-(25-35) injections into the rat nucleus basalis. , 1995, Neuroscience.

[80]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[81]  P. J. Kamphuisu,et al.  Nutrition and Alzheimer ' s disease : pre-clinical concepts , 2022 .